Citations

Clear

3042 citation(s) found for "Kumar, S".

Temporal EHR Models Detect Rare Disease Years Before Diagnosis
Yang, Lu, Ng, Pauline, Lun, Ming Yin, Tunstall, Tate, Meyers, Lindsay, Osundiji, Mayowa, Im, Kate, Lavertu, Adam , Rabinowitz, Matt, Tunstall, Tate, Kumar, Akash

Mayo Clinic

No container title available | September 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.10.26362561 Get It

Background. Rare diseases collectively affect an estimated 300 million people worldwide, yet patients wait an average of 4-8 years for a correct diagnosis after visiting multiple physicians, accumulating unexplained findings, and suffering preventable disease progression before a unifying diagnosis is reached. Electronic health records (EHRs) capture this pre-diagnostic trajectory in rich detail, but conventional methods typically collapse years of longitudinal phenotypic signals into a single static snapshot; our approach instead models this temporal structure directly. Methods. We conducted a retrospective cohort study using longitudinal EHR data from approximately 3 million patients at Mayo Clinic Platform_Accelerate. Cases were patients with confirmed diagnoses of 10 rare diseases; controls (~5,200 per disease) had no record of any rare disease. HPO phenotype terms were extracted from clinical notes and laboratory results using a medspaCy NLP pipeline; ICD codes were grouped at three-character level. We developed and trained two temporal models, GRU-Attn and Conformer, that encode patient histories as quarterly time-binned sequences spanning up to 30 years, and compared these against three static baselines (CatBoost, XGBoost, logistic regression). Models were evaluated systematically at prediction horizons h = 1-10 years before diagnosis. Results. In the full held-out cohort benchmark, temporal models outperformed static baselines across the large majority of diseases and prediction horizons, with the advantage widening substantially as the horizon lengthened. At 1-2 years prior to diagnosis, mean AUROC was 0.928 (GRU-Attn) versus 0.871 (CatBoost); at 6-10 years prior to diagnosis, 0.726 versus 0.693, with static models degrading to near-chance for some diseases. Combining HPO and ICD features yielded the strongest performance, with a mean gain of +0.063 AUROC over the best single source at 1-2 years prior to diagnosis. Separately, in a manually curated cohort of 143 confirmed-undiagnosed cases with extended EHR histories, GRU-Attn identified 138 cases before first disease mention and all 143 cases before formal diagnosis at the prespecified 99th-percentile specificity threshold, with median lead times of 1.1-8.3 years and 1.9-21.7 years, respectively. Conclusions. By learning from the temporal trajectory of phenotypic signals rather than their static aggregate, temporal EHR models improved retrospective early detection performance across several rare diseases, most powerfully for conditions where pre-diagnostic findings accrue gradually and heterogeneously over years. These results show that longitudinal EHR trajectories carry rare-disease signal beyond static phenotypic burden and support prospective evaluation of temporal EHR modeling for rare-disease risk stratification.
Prediction of Rhinologic Surgery Within 90 Days Using Item‐Level SNOT‐22 Responses: A Multisite Machine Learning Study of 35,170 Patients
Sramek, Michael , Kumar, Nitish , Patel, Shrinath, Miglani, Amar , Marino, Michael, Lal, Devyani , Kumar, Nitish , Lal, Devyani , Marino, Michael J.

Mayo Clinic

International Forum of Allergy & Rhinology | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/alr.70273 | PMID 42722008 Get It

ABSTRACT Background Optimizing access to cost‐effective care in capacity‐constrained health systems is a contemporary imperative. We evaluated whether machine learning (ML) models using patient‐reported data could optimize access for patients requiring surgical care in rhinology clinics, without need for CT imaging. The outcome was defined as any rhinologic surgery within 90 days of initial evaluation. Methods A de‐identified electronic dataset from patients seen at five distinct sites within an integrated healthcare system between 2018 and 2025 was used to train models. Demographic data and 22‐item Sinonasal Outcome Test (SNOT‐22) responses were studied. Models were trained using stratified 5‐fold cross‐validation with an 80% development cohort and validated in a 20% held‐out validation cohort. Hyperparameters were optimized with Optuna. The primary outcome was performance of any rhinologic surgical intervention within 90 days of initial SNOT‐22. Results Data from 35,170 patients were evaluated. Item‐level responses outperformed use of total SNOT‐22 score in the models. Among models, XGBoost demonstrated best discrimination with AUC of 0.70 (95% CI, 0.69–0.71), outperforming logistic regression (0.66), random forest (0.63), and TabNet (0.66) (all p < 0.001). At optimal threshold, XGBoost achieved 66% sensitivity, 64% specificity, 28% PPV, and 90% NPV. Top predictors for surgery were age, nasal blockage, facial pain or pressure, and decreased sense of smell or taste. Validation on the held‐out cohort remained stable (AUC 0.70), with strong discrimination across sites despite surgical rates ranging from 11.5% to 27.4%. Conclusions Demographics and item‐level SNOT‐22 responses were successful in developing an ML model that demonstrated moderate discrimination and high NPV (90%) for performance of surgery within next 90 days. ML models balanced with human oversight may accelerate triage and optimize surgical yield for rhinology clinics.
Laparoscopic Cholecystectomy Is a Time-Sensitive Operation: National Outcomes Associated With Delayed Surgery
Bhatt, Himani , Orduno Villa, Nancy , Kumar, Jayant, Vakil, Deep , Singh, Sahajpreet, Young, Samantha, Curcio, Gary, Rosenthal, Andrew , Parreco, Joshua, Curcio, Gary, Rosenthal, Andrew, Parreco, Joshua P.

Mayo Clinic

The American Surgeon™ | September 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261486928 | PMID 42709057 Get It

Background Competition for urgent and emergent operating-room access is a significant challenge in many hospitals. Evidence-based benchmarks for early intervention are well established for emergencies like acute appendicitis or hip fracture. In contrast, laparoscopic cholecystectomy for acute cholecystitis or symptomatic cholelithiasis is often delayed. The purpose of this study was to evaluate the clinical and economic impact of delays in laparoscopic cholecystectomy across the US. Methods The Nationwide Readmissions Database was queried for patients aged ≥18 years admitted between 2021 and 2022 undergoing urgent or emergent laparoscopic cholecystectomy. Patients were stratified based on operative timing (<3 vs ≥ 3 days). The primary outcome was 30-day readmission. Secondary outcomes included VTE, SSI, and total cost. Propensity score matching (1:1) was performed using 46 covariates. Linear regression assessed the cost associated with each additional hospital day prior to surgery, with a subgroup analysis of safety-net hospitals. Results Among 136,893 patients, 24,496 (17.9%) experienced delayed laparoscopic cholecystectomy. After matching (n = 48,992), delays were associated with increased odds of readmission (9.5%; OR 1.22 [1.15-1.29], P < 0.001) and VTE (1.5%; OR 1.51 [1.30-1.77], P < 0.001). SSI (0.2%) was not significantly different. The mean total cost was $25,957 ± $21,609 for delayed patients vs $20,784 ± $20,027 for early surgery. Linear regression revealed an incremental cost of $1,695 per additional hospital day prior to surgery, rising to $2071 per day in safety-net hospitals ( P < 0.001). Discussion Delays in laparoscopic cholecystectomy have significant clinical and economic impacts, underscoring the urgent need for national benchmarks to standardize operative timing and reduce disparities for patients in safety-net hospitals.
Longitudinal Data from a Large, Multi-Target Stool DNA Colorectal Cancer Screening Program
Garg, Sushil Kumar , Hintz, Carley F , Kolarik, Hannah J , Mau, Brayden , Hubers, Jeffrey , Arce, Victor, Ebner, Derek W. , Gurudu, Suryakanth, Bi, Yan , Greenwood, Jason D. , Chaudhary, Rajeev, Hubers, Jeffery , Gurudu, Suryakanth R, Greenwood, Jason , Kisiel, John B , Ebner, Derek , Kolarik, Hannah , Arce, Victor, Kisiel, John B.

Mayo Clinic

American Journal of Gastroenterology | September 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.14309/ajg.0000000000004196 | PMID 42690929 Get It

Background & Aims: Multi-target stool DNA (mt-sDNA) is an established stool-based colorectal cancer screening test, yet long-term performance is not well-described. We evaluated follow-up colonoscopy rates & quality, neoplasia yield, and repeat-testing adherence over 10 years with an integrated screening program. Methods: We assembled a retrospective cohort of mt-sDNA tests (September 2014–July 2025) within a multi-site health system. A validated large-language-model pipeline extracted colonoscopy, pathology, and quality endpoints from free-text reports. Detection outcomes (adenoma detection rate, advanced neoplasia, modified advanced adenoma, sessile serrated lesion (SSL), and negative exams) were calculated among high-quality exams; adenocarcinoma, bowel preparation adequacy, and cecal intubation rate (CIR) used all screening exams. We assessed colonoscopy completion ≤1 year after positive mt-sDNA, follow-up colonoscopy findings, findings by time-to-colonoscopy, and adherence to repeat mt-sDNA after negative result. Results: Among 148,624 tests in 110,410 individuals, positivity was 13.6%. Of 19,506 positives, 65.1% completed colonoscopy within 12 months (median 82 days). Colonoscopy after a positive mt-sDNA had high yield: advanced adenoma diagnosis was 30.7%; adenocarcinoma was 1.3%. Of patients who had colonoscopy within 3 years of a negative mt-sDNA test, 45.2% had adenoma/serrated lesion, 9.3% had advanced adenoma and 0.5% had colon cancer. Adenoma detection rate after positive mt-sDNA (>50%) exceeded specialty society quality benchmarks and increased over time; Longer intervals (>6 months) to colonoscopy after a positive test were associated with higher advanced adenoma (trend P=0.001).After an initial negative mt-sDNA, only 35.3% were screened again by mt-sDNA testing within 3 years. Conclusions: Over a decade,mt-sDNA screening achieved high colonoscopy qualitybut revealed critical gaps in the care cascade. One-third of positive tests lacked timely follow-up and nearly two-thirds of negative tests were not repeated on schedule, suggesting opportunities for system-level interventions.
Artificial Intelligence‐Estimated Intrapancreatic Fat and Its Relationship to Familial and Germline Pancreatic Cancer Risk
Konikoff, Tom , Takahashi, Hiroaki , Suman, Garima , Mishra, Anup Kumar , Korfiatis, Panos, Carlson, Erin E., Bamlet, William R., Pradeep, Aishwarya , Harper, Kelly, Delgado, Adriana, Goenka, Ajit H. , Oberg, Ann L. , Takahashi, Hiroaki , Nugen, Fred , Mishra, Anup , Pradeep, Aishwarya , Doering, Karen A , Erickson, Bradley J , Goenka, Ajit Harishkumar , Takahashi, Naoki , Oberg, Ann L , Majumder, Shounak , Janssens, Laurens , Nugen, Fred , Carlson, Erin E., Bamlet, William R. , Doering, Karen A. , Delgado, Adriana, Erickson, Bradley J. , Takahashi, Naoki , Majumder, Shounak

Mayo Clinic

United European Gastroenterology Journal | August 29, 2026 | Volume: 14 | Issue: 7 | Pages: No page available

10.1002/ueg2.70279 | PMID 42666046 Get It

ABSTRACT Background Family history of pancreatic cancer (PC), pathogenic germline variants (PGVs), and increased intrapancreatic fat (IPF) are individually associated with increased PC risk. Whether IPF is elevated in high‐risk individuals (HRIs) with PC family history or PGVs is unknown. Although MRI is the preferred modality for IPF measurement, region‐of‐interest–based approaches are prone to sampling bias because pancreatic fat is heterogeneously distributed. We aimed to compare IPF among HRIs and matched non‐HRI controls using an Artificial intelligence (AI)‐based tool for whole pancreatic IPF measurement applied to magnetic resonance imaging (MRI). Methods We developed and validated a deep‐learning pipeline for IPF measurement that incorporates automated pancreas segmentation on T1‐weighted MRI images registered to the corresponding iterative decomposition of water and fat with echo asymmetry and least squares estimation images to compute IPF using proton density fat fraction (PDFF). This pipeline was used to quantify IPF and assess IPF distribution patterns in 85 HRIs and 170 non‐HRIs matched 1:2 for age, sex, BMI, and diabetes status. A surface erosion approach was developed to minimize the impact of peripancreatic fat on IPF measurement. Linear models adjusting for matching variables were used to assess associations. Results Model‐expert agreement for whole‐pancreas PDFF was excellent (intraclass correlation coefficient 0.99; 95% CI, 0.98–0.99 mean absolute error 1.4%). Mean PDFF did not differ between HRIs and controls (25.8% [11.5] vs. 26.9% [11.4]; p = 0.32). PDFF increased with age ( p = 0.015), male sex ( p < 0.001), presence of diabetes ( p = 0.009), BMI ( p < 0.001). IPF distribution patterns did not differ by risk group. Conclusion An AI‐based approach provides accurate, scalable, and objective assessment of IPF quantity and distribution. IPF quantity and spatial distribution do not appear to differ based on germline or familial predisposition to PC.
Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse‐Risk Subtype in AL Amyloidosis With Inferior Long‐Term Survival
Hellou, Tamer , Gauto‐Mariotti, Estefania , Alnughmush, Ahmed , Baughn, Linda B. , Kapoor, Prashant , Zanwar, Saurabh , Suzuki, Shinichiro , Steinhardt, Maximilian , Packard, Daniel George , Kourelis, Taxiarchis , Hayman, Suzanne R. , Hwa, Yi L. , Fonder, A., Hobbs, Miriam, Warsame, Rahma, Abdallah, Nadine , Kyle, Robert A., Kumar, Shaji , Mariotti, Estefania Gauto , Steinhardt, Maximilian , Packard, Daniel G , Kourelis, Taxiarchis V, Buadi, Francis K , Dingli, David , Leung, Nelson , Hwa, Yi L , Cook, Joselle M , Binder, Moritz , Abdallah, Nadine H , Lin, Yi , Go, Ronald S , Rajkumar, S Vincent , Gonsalves, Wilson , Kumar, Shaji K , Gertz, Morie A , Dispenzieri, Angela , Muchtar, E , Baughn, Linda B , Hellou, Tamer , Buadi, Francis K. , Dingli, David , Leung, Nelson , Fonder, Amie , Hobbs, Miriam, Warsame, Rahma , Cook, Joselle , Binder, Moritz , Lin, Yi , Go, Ronald S. , Kyle, R., Rajkumar, S. Vincent , Gonsalves, Wilson I. , Gertz, Morie A. , Dispenzieri, Angela , Muchtar, Eli

Mayo Clinic

American Journal of Hematology | August 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70484 | PMID 42638274 Get It

ABSTRACT The prognostic relevance of multiple myeloma (MM)‐defined high‐risk (HR) cytogenetic abnormalities in AL amyloidosis is incompletely defined. We retrospectively evaluated 517 newly diagnosed AL amyloidosis patients seen at Mayo Clinic between 2012 and 2021 who had baseline plasma cell FISH. HR cytogenetics were defined as t (4;14), t (14;16), t (14;20), del(17p), or 1q gain/amplification (+1q). HR abnormalities were identified in 151 patients (29%); +1q accounted for most HR cases (122/151, 81%). Compared with standard‐risk (SR), patients harboring +1q demonstrated a greater clonal disease burden, including higher dFLC and bone marrow plasma cells, greater intact immunoglobulin secretion, higher plasma cell proliferative index, and enrichment for modified SLiM‐CRAB features. Hematologic and organ response patterns of +1q patients were generally comparable to SR patients, whereas non‐1q HR patients had a higher proportion of early hematologic responses. Patients harboring +1q demonstrated significantly inferior overall survival (OS) compared with both non‐1q HR patients and SR patients (median OS 57 months vs. not reached vs. 120 months, p = 0.02). In multivariable piecewise Cox analysis, the adverse prognostic impact of +1q was most evident beyond 24 months from diagnosis (HR 2.89, 95% CI 1.64–5.09, p < 0.001), whereas non‐1q HR lesions were not independently prognostic. These findings suggest that +1q identifies a biologically distinct AL amyloidosis subset characterized by plasma cell–dominant features and inferior long‐term disease control. In contrast, other MM‐defined HR cytogenetic abnormalities appear to have limited prognostic relevance in AL amyloidosis.
Older Age, STAG2 , and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents
Warraich, Momna , Kumar, Sudhesh , Fatima, Mahnoor , McCullough, Kristen , Al‐Kali, Aref , Begna, Kebede H. , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Matin, Aasiya , Litzow, Mark R. , Patnaik, Mrinal M. , Pardanani, Animesh , Foran, James M. , Sproat, Lisa, Khera, Nandita , Tefferi, Ayalew , Gangat, Naseema , Saliba, Antoine N. , Alkhateeb, Hassan B , Mangaonkar, Abhishek A. , Saliba, Antoine N , Matin, Aasiya , Litzow, Mark R. , Hogan, William J , Shah, Mithun V , Patnaik, Mrinal , Pardanani, Animesh , Foran, James M , Khera, Nandita , Tefferi, Ayalew , Gangat, Naseema , McCullough, Kristen B , Saliba, Antoine N , Alkhateeb, Hassan B. , Hogan, William J. , Shah, Meera

Mayo Clinic

American Journal of Hematology | August 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70480 | PMID 42633550 Get It

ABSTRACT Venetoclax (Ven) plus hypomethylating agents (HMA) is standard frontline therapy for newly diagnosed AML (ND‐AML) patients unfit for intensive chemotherapy and is also considered in younger, fit patients. However, consolidation with allogeneic stem cell transplant (ASCT) is often required to secure durable remission. The current study examines posttransplant outcomes in patients with ND‐AML treated with frontline Ven‐HMA who subsequently underwent ASCT. A total of 111 ND‐AML patients (58% male, 60% secondary/therapy‐related, median age 70 years [range, 37–80]) received a median of 3 cycles of Ven‐HMA. Mutations at the time of diagnosis included RUNX1 (18%), SRSF2 (17%), TP53 (16%), ASXL1 , IDH2 , K/NRAS , TET2 (14% each), STAG2 (11%), DNMT3A (8%). All patients were in CR/CRi at the time of transplant including 88% after Ven‐HMA. Measurable residual disease (MRD) by flow cytometry was detectable in 18/76 (24%) patients. Donors were mostly HLA‐matched unrelated (75%); 51% receiving fludarabine/melphalan conditioning and 67% posttransplant cyclophosphamide. At a median follow‐up of 15 months, 42 (38%) of patients have died and 18 (16%) experienced posttransplant relapse. Median posttransplant survival was not reached (NR), with 1‐, 2‐, 3‐year survival rates of 69%/60%/57%, respectively. On multivariate analysis, age ≥ 65 years, STAG2 mutation ( STAG2 MUT ) , and DNMT3A MUT were associated with superior posttransplant survival. Patients were stratified into low‐ (0–1 point), intermediate‐ (2 points), and high‐risk (3 points); age < 65 years, STAG2 wild type, and DNMT3A wild type, with 3‐year survival rates of 89%, 59%, and 19%, respectively ( p < 0.01). Taken together, age, STAG2 MUT and DNMT3A MUT stratified posttransplant survival in Ven‐HMA treated patients with ND‐AML.
Tissue and blood-based predictive biomarkers in hepatocellular carcinoma immunotherapy: synthesis of 2023–2026 evidence and a proposed clinical integration framework
Sisodia, Rajvardhan , Bharadwaj, Hareesha Rishab , Sonaiya, Sneh, Shah, Yash, Dhali, Arkadeep, Abdul, Rahman, Khan, Sajjad Ahmad, Alsakarneh, Saqr, Mandal, Saikat, Bharadwaj, Hareesha Rishab , Sharma, Ashish , Tan, Joecelyn Kirani , Kumar, Harendra , Sonaiya, Sneh , Ali, Hassam , Dhali, Arkadeep , Alsakarneh, Saqr , Dahiya, Dushyant Singh , Mandal, Saikat

Mayo Clinic

Frontiers in Oncology | August 19, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.3389/fonc.2026.1894185 | PMID 42689129 Get It

Atezolizumab-bevacizumab and durvalumab-tremelimumab have established immunotherapy as a first-line standard of care in advanced hepatocellular carcinoma (HCC). Yet, objective response rates (ORRs) remain confined to approximately 15-20%, and no validated predictive biomarker exists for patient selection. Unlike melanoma and lung cancer, conventional markers, including programmed death-ligand 1, microsatellite instability-high status, and tumor mutational burden, have not demonstrated reliable predictive value in HCC. Prior narrative reviews comprehensively catalogued the biomarker landscape through 2022 but predate a wave of clinically significant publications. This narrative review synthesizes evidence published between 2020 and 2026, with particular emphasis on 2023–2026 data, within a unified clinical framework not provided by prior reviews. We critically evaluate tissue-based biomarkers, including the AI-derived Atezolizumab-Bevacizumab Response Signature-Pathology model, spatial multiplex immunohistochemistry, and β-catenin mutational profiling; blood-based biomarkers encompassing circulating tumor DNA for minimal residual disease detection and peripheral immune phenotyping; and serum indices including the CRAFITY score and neutrophil-to-lymphocyte ratio. Hepatitis B virus etiology and non-alcoholic steatohepatitis are discussed as biological modifiers of biomarker performance. We propose an original biomarker-guided clinical algorithm, a comparative clinical readiness table, and a disease-continuum biomarker timeline as practical tools for clinicians and trialists. Prospective biomarker-enrichment trials represent the most critical next step toward clinical translation.
PSMA PET/CT for Radiation Planning and Response Assessment in Intracranial High-Grade Gliomas
Upadhyay, Rituraj , Kumar, Pavnesh , Tang, Bingfeng , Bello‐Pardo, Erika, Mohtashami, Hamid, Singh, Pawan, Giglio, Pierre , Wu, Kyle , Elder, J Brad, Beyer, Sasha, Singh, Raj, Raval, Raju R. , Thomas, Evan , Zhang, Chi , Ivanidze, Jana, Yadav, Divya , Mohtashami, Hamid, Ivanidze, Jana , Palmer, Joshua D. , Giglio, Pierre , Wu, Kyle C , Ivanidze, Jana , Palmer, Joshua D

Mayo Clinic

Neuro-Oncology Advances | August 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/noajnl/vdag217 | PMID 42828195 Get It

Lay Summary Glioblastoma is an aggressive brain cancer, and it can be difficult to tell whether changes seen on scans after radiation treatment represent tumor growth or treatment-related effects. The authors of this study wanted to evaluate whether a specialized imaging test called PSMA PET could help define tumor boundaries for radiation planning and distinguish tumor progression from treatment-related changes. To do this, they performed PSMA PET scans in 27 patients with high-grade gliomas, including patients undergoing radiation planning and patients being evaluated for possible tumor recurrence. They found that tumors showed higher PSMA PET signal than surrounding tissue, that PSMA PET sometimes identified tumor beyond what was visible on standard MRI, and that it correctly distinguished tumor progression from treatment-related changes in most patients.
Clinical, Genetic, and Endocrine Features of Bardet‐Biedl Syndrome in a Pediatric and Adult Cohort
Hassan, Doha , Salama, Mostafa , Muthusamy, Kalpana , Haqq, Andrea M., Scruggs, Brittni A. , Lanpher, Brendan C. , Tan, Queenie K.‐G. , Cramer, Carl H. , Rabatin, Amy E. , Koball, Afton M. , Darr, Kahlen , Bratcher, Paul M., Lamothe, Kathleen, Tenley, Jennifer B., Kumar, Seema , Tan, Queenie K-G , Biggs, Bridget K , Rabatin, Amy E , Koball, Afton , Schimmenti, Lisa A , Kumar, Seema , Salama, Mostafa , Scruggs, Brittni A , Cramer, Carl H , Haqq, Andrea M. , Biggs, Bridget K. , Schimmenti, Lisa A.

Mayo Clinic

American Journal of Medical Genetics Part A | August 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajmg.a.70276 | PMID 42596080 Get It

ABSTRACT Bardet‐Biedl syndrome (BBS) is a rare autosomal recessive disorder characterized by clinical and genetic heterogeneity. Data on the prevalence of clinical manifestations and comorbidities in BBS, particularly in pediatric patients, are limited. This study aimed to assess the prevalence and various manifestations of endocrine and other clinical comorbidities among pediatric and adult patients with BBS. This retrospective chart review included pediatric and adult patients with BBS evaluated at an academic tertiary care center in the United States between 2000 and 2024. The study included 31 patients (7 children and 24 adults) with seven identified pathogenic variants associated with BBS. The most common genetic etiology was biallelic variants in BBS1 (36%). Obesity was diagnosed in 86% of children and 100% of adults. No children had diabetes or prediabetes, whereas 46% of adults were affected. Dyslipidemia was identified in 29% of children and 46% of adults. No thyroid abnormalities were identified in children, whereas 25% of adults were affected. Retinal dystrophy was present in 71% of children and 96% of adults. Polydactyly was observed in 100% of children and 75% of adults. Chronic kidney disease was present in 29% of children and 63% of adults. This study highlights the clinical heterogeneity and substantial multisystem burden of BBS across pediatric and adult patients. The greater prevalence of diabetes/prediabetes, dyslipidemia, thyroid abnormalities, chronic kidney disease, and visual impairment among adults suggests that these complications may emerge or progress over time. Early recognition, proactive longitudinal surveillance, and comprehensive multidisciplinary care are essential to optimize management across the lifespan.